Skip to main content
. 2014 Jun 18;105(7):825–832. doi: 10.1111/cas.12428

Table 1.

Distribution of patient characteristics and prognosis analysis in Chinese patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE) (n = 448)

Variable Total, n (%) (n = 448) Deaths, n (%) (n = 339) Adjusted HR (95% CI) P-value
Age, years
 ≤53 222 (49.6) 168 (49.6) Ref.
 >53 226 (50.4) 171 (50.4) 1.13 (0.89–1.42) 0.310
Sex
 Female 57 (12.7) 40 (11.8) Ref.
 Male 391 (87.3) 299 (88.2) 1.27 (0.90–1.77) 0.170
HBV infection
 Negative 65 (14.5) 48 (14.2) Ref.
 Positive 383 (85.5) 291 (85.8) 0.84 (0.61–1.17) 0.300
PVTT
 No 314 (70.1) 221 (65.2) Ref.
 Yes 134 (29.9) 118 (34.8) 1.92 (1.49–2.46) <0.001
Child–Pugh score
 A 431 (96.2) 324 (95.6) Ref.
 B 17 (3.8) 15 (4.4) 1.64 (0.97–2.75) 0.060
TNM stage
 I + II 221 (49.3) 142 (41.9) Ref.
 III + IV 227 (50.7) 197 (58.1) 1.56 (1.23–1.98) <0.001
Serum AFP, μg/L
 <400 231 (51.6) 157 (46.3) Ref.
 ≥400 217 (48.4) 182 (53.7) 1.51 (1.20–1.89) <0.001
Treatment
 TACE 366 (81.7) 299 (88.2) Ref.
 TACE + other 82 (18.3) 40 (11.8) 0.42 (0.30–0.59) <0.001

Adjusted by age, sex, hepatitis B virus (HBV) infection, portal vein tumor thrombus (PVTT), tumor stage, serum α-fetoprotein (AFP), and treatment, where appropriate. ‡Significant P-values (<0.05) are in bold. CI, confidence interval; HR, hazard ratio; Ref., reference; TACE, transcatheter arterial chemoembolization.